Viktor Grünwald, Professor of Urologic Oncology at University Hospital Essen, shared on LinkedIn:
“Just out, our German real-world cohort of LEN+PEM in mRCC patients, led by our rising star Ramona Stellmach of the GUARDIANS network
- therapy modifications are frequent in RW-cohorts
- includes pts. who are not trial-eligible
- confirms efficacy in broader population
- supports the use of LEN-PEM in RW setting”
Authors: Ramona Stellmach et al.
Read more about mRCC on OncoDaily.